Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imbruvica Boosts CLL Lead With First-Line Claim

This article was originally published in Scrip

Executive Summary

AbbVie Inc. and Johnson & Johnson's BTK inhibitor Imbruvica (ibrutinib) has reinforced its lead position in the chronic lymphocytic leukemia market with a first-line indication from FDA.

You may also be interested in...



Despite Pricing Pressure, Humira Performing Strongly Across Most Metrics, Abbvie Says

Humira continues its strong growth pace through volume gains and market share across therapeutic categories, CEO Gonzalez says, while leukemia drug Imbruvica also had a solid third quarter.

Despite Pricing Pressure, Humira Performing Strongly Across Most Metrics, Abbvie Says

Humira continues its strong growth pace through volume gains and market share across therapeutic categories, CEO Gonzalez says, while leukemia drug Imbruvica also had a solid third quarter.

J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches

Pharma says pipeline is poised to continue growth with 10 NMEs to be approved between 2015-2019 that could produce blockbuster sales. J&J adds that it’s planning 40 line extensions, with 10 that could yield $500m annually each.

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel